Clinical Trials Logo

Meibomian Gland Dysfunction clinical trials

View clinical trials related to Meibomian Gland Dysfunction.

Filter by:

NCT ID: NCT04884243 Completed - Clinical trials for Meibomian Gland Dysfunction

Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction

Start date: September 5, 2021
Phase: Phase 2
Study type: Interventional

STUDY DESIGN Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study. Duration: 3 months of TID treatment. Treatment Groups, Dosing, and Treatment Regimen: Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle

NCT ID: NCT04658927 Completed - Clinical trials for Meibomian Gland Dysfunction

Dextenza With ILUX for Treatment of MGD

Start date: January 4, 2021
Phase: Phase 4
Study type: Interventional

To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing iLUX MGD Treatment System.

NCT ID: NCT04567329 Completed - Dry Eye Disease Clinical Trials

Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

Start date: November 18, 2020
Phase: Phase 3
Study type: Interventional

The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).

NCT ID: NCT04500821 Completed - Clinical trials for Meibomian Gland Dysfunction

Evaluation of the LipiFlow System With a New Activator

Start date: October 2, 2020
Phase: N/A
Study type: Interventional

Minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. The investigator or designee will perform LipiFlow treatment with the Activators LFD-2100 on both eyes of a subject. The data from the treatment reports generated by the LipiFlow console and from the questionnaire will be used to assess the clinical utilization of the Activator LFD-2100. This study will be conducted in up to four sites in the USA.

NCT ID: NCT04469998 Completed - Clinical trials for Meibomian Gland Dysfunction

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

Start date: June 16, 2020
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating posterior blepharitis associated with Meibomian Gland Disease (MGD)

NCT ID: NCT04457648 Completed - Clinical trials for Meibomian Gland Dysfunction

Manuka Honey Eye Drops VS Conventional Treatment of Meibomian Gland Dysfunction Related Dry Eye Disease

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

Assessor-masked (Single blind, randomized controlled trial comparing the conventional treatment group to an interventional group using 16% Manuka Honey topical eye drops.

NCT ID: NCT04454983 Completed - Dry Eye Clinical Trials

Lipiflow vs iLux Patient Acceptance and Comfort Study

Start date: January 11, 2020
Phase: N/A
Study type: Interventional

This study was designed to compare patient acceptance, comfort, and preference between two meibomian gland clearing devices (Lipiflow vs, iLux). Primary Objective was to compare patient comfort as assessed by Likert-style scale questionnaire following each bilateral procedure. Secondary Objective was to compare overall experience and treatment preference as assessed by Likert-style questionnaire following each bilateral procedure. Both devices are exempt from IDE regulations [21 CFR 812.2(c)].

NCT ID: NCT04391959 Completed - Clinical trials for Meibomian Gland Dysfunction

Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

Start date: July 17, 2020
Phase: Phase 2
Study type: Interventional

AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)

NCT ID: NCT04314362 Completed - Clinical trials for Meibomian Gland Dysfunction

Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

Start date: July 14, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study.

NCT ID: NCT04310969 Completed - Dry Eye Syndromes Clinical Trials

Clinical Effect of MiboFlo in Dry Eye Patients

Start date: April 3, 2020
Phase: N/A
Study type: Interventional

The aim of this prospective study is to compare the changes between the patients receiving traditional treatment and the patients with MiBoFlo, evaluating the effectiveness of MiBoFlo.